Asthma pill for kids shows promise, but study cut short
NCT ID NCT03650400
First seen Jan 17, 2026 · Last updated May 20, 2026 · Updated 19 times
Summary
This study tested a chewable tablet called fevipiprant in children aged 6 to 12 with asthma. The goal was to measure how the drug moves through the body and check its safety. Only 11 children took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Minneapolis, Minnesota, 55402, United States
-
Novartis Investigative Site
Columbia, Missouri, 65203, United States
-
Novartis Investigative Site
Tulsa, Oklahoma, 74136, United States
-
Novartis Investigative Site
Boerne, Texas, 78006, United States
-
Novartis Investigative Site
El Paso, Texas, 79903, United States
-
Novartis Investigative Site
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.